Associated Papers
Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India.
Sharma-Oates A et al.
Precision Clinical Medicine, 2018
Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
Podralska M et al.
Bmc Cancer, 2018
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM et al.
Familial Cancer, 2018
Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Lener MR et al.
International Journal of Cancer, 2016
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Tecza K et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2015
Dupuytren's disease and the risk of malignant neoplasms.
Zyluk A et al.
Hereditary Cancer in Clinical Practice, 2014
Hereditary breast and ovarian cancer susceptibility genes (review).
Kobayashi H et al.
Oncology Reports, 2013
An inherited NBN mutation is associated with poor prognosis prostate cancer.
Cybulski C et al.
British Journal of Cancer, 2013
Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
Haytural H et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2013
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Karami F et al.
Biomed Research International, 2013
Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Oluwagbemiga LA et al.
Springerplus, 2012
The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N et al.
Clinical Genetics, 2010
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV et al.
Clinical Genetics, 2010
Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI et al.
Molecular Carcinogenesis, 2010
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Chang S et al.
The Journal of Clinical Investigation, 2009
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.
Armaou S et al.
British Journal of Cancer, 2009
BRCA1 mutations and prostate cancer in Poland.
Cybulski C et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ecp), 2008
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.
Kote-Jarai Z et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ et al.
International Journal of Radiation Biology, 2003
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.
Cortesi L et al.
Genes, Chromosomes & Cancer, 2000
A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.
Dong J et al.
Human Genetics, 1998